MARKET OUTLOOK
The global infertility (testing and treatment) market is expected to progress at a CAGR of 7.14% over the forecast duration 2019-2027.
The WHO statistics have shown that out of every six couples, at least one of them suffers from infertility issues worldwide. Rise in the medical tourism for infertility treatments, a more convenient surrogacy law and various initiatives for creating awareness of infertility treatments are driving the growth of the market globally. Also, the rising pollution levels have led to growing infertility, which is further boosting the market demand for infertility (testing and treatment) devices globally. However, the market is facing challenges from traditional infertility treatments. Also, these testing and treatment concerning infertility issues are considered to be a taboo in society, especially amongst men.
The infertility (testing and treatment) market is segmented into male, female and end-user segments. The end-user segment is divided into fertility & surgical centers, hospitals & research laboratories and cryobanks. The male segment is divided into two substituents, the male infertility testing and male infertility treatment. The male infertility treatment segment is classified into sperm retrieval treatment, intracytoplasmic sperm injection (ICSI), microsurgical sperm aspiration (MESA), in-vitro fertilization (IVF), intrauterine insemination (IUI), assisted reproductive technique (ART), varicocele repairs, testicular sperm extraction (TESE), vasovasostomy and vasoepididymostomy (vasectomy reversal). The male infertility testing segment is divided into sperm penetration assay, microscopic examination, computer-assisted semen analysis (CASA), sperm agglutination, oxidative stress analysis, DNA fragmentation and others.
REGIONAL OUTLOOK
The infertility (testing and treatment) market are segmented into regions such as Europe, Latin America, North America, Middle East & Africa and the Asia-Pacific. The North America region is expected to grow at a steady rate as women in this region prefer to have pregnancies at an older age, thus leading to high chances of infertility. Also, IVF treatment costs are economical. The European region is currently dominating the infertility market mainly due to high diagnostics rates, public awareness and high disposable incomes of the population. The Asia-Pacific region is progressing at the highest growth rate in the forecast period, owing to the huge investments by various governments in the pharmaceutical industries and healthcare centers.
COMPETITIVE OUTLOOK
The key players in the global infertility (testing and treatment) market are Esco Micro Pte. Ltd., Irvine Scientific, Endo Pharmaceuticals, Thermo Fisher Scientific Inc., Origio, OvaScience, Genea, Halotech DNA, Vitrolife AB, Merck, Quest Diagnostic, Ferring Pharmaceuticals, Andrology Solutions, The Cooper Companies, Inc. and Progyny.
Progyny, Inc. is a US-based healthcare company that provides fertility services to consumers and employers. It provides a non-invasive time-lapse imaging system to aid in early embryo selection; a no-restriction IVF package plan for patients; egg freezing options through its network of fertility doctors across the United States; and a patient-matching technology platform for the fertility industry. The company entered into a strategic alliance with Mercer L.L.C. in January 2017 to provide employers and their employees with an innovative fertility benefit product that will help organizations to considerably cut down on NICU and associated high-risk maternity-related costs while increasing access and positive outcomes.